Oncology Central panel discussion: real-world data in clinical trials


Wednesday 3 February 2021
07:00 [PST] 10:00 [EST] 15:00 [GMT]

Alternative time-zones

This panel discussion, hosted by our sister site, Oncology Central, in association with Agendia (CA, USA), will focus on the future of using real-world data (RWD) alongside clinical trials and the potential challenges that need to be overcome. It also aims to assess how clinical trials are being shaped by research and the impact of COVID-19. 

What will you learn?

  • How outcomes research is shaping the design of clinical trials
  • The future of RWD use alongside clinical trials
  • How RWD can help payers with the value of diagnostics
  • How COVID-19 has changed treatment habits

Who may this interest?

  • Researchers and clinicians working in the multidisciplinary field of RWD and clinical trials
  • Regulatory bodies
  • Oncology investors



William Audeh
Chief Medical Officer
Agendia (Los Angeles, USA)

William Audeh, MD, MS is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program.

Dr Audeh also served as Director of the Medical Oncology Training Program for Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai, and is Associate Clinical Professor of Medicine at the UCLA David Geffen School of Medicine. Dr Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics, and targeted cancer therapy.

Dr Audeh received his medical degree from the University of Iowa and an M.S. Degree in Genetics from the University of Minnesota. He went on to complete his residency in Internal Medicine as well as a fellowship in Medical Oncology at Stanford University Medical Center. He is board certified on internal medicine and medical oncology, and is a member of the American Society of Clinical Oncology and American Association of Cancer Research.



Jacob Adashek
Internal medicine resident
University of South Florida and H. Lee Moffitt Cancer Center & Research Institute (FL, USA)

Dr Adashek is a second-year internal medicine resident at the University of South Florida and H. Lee Moffitt Cancer Center & Research Institute. He is interested in oncology and clinical trial design. He has presented research at various international meetings and has contributed to work published in top medical journals worldwide. Dr Adashek’s work focuses mainly on targeted and immunotherapeutics and novel combinations in n-of-1 trial designs.



Gorana Capkun
Head RWE Enablement
Novartis Oncology (Basel, Switzerland)

Gorana Capkun is heading Enablement of Real World Evidence at Novartis Oncology. She is a published leader within the healthcare industry, with a particular interest in identifying novel ways of creating evidence, defining value, developing and bringing healthcare solutions to improve the lives of patients. Gorana is a strong believer in the power of dialogue between all partners in finding sustainable solutions to healthcare challenges.

She successfully combines her knowledge in statistics, health economics, real world evidence and market access with her experience from all phases of drug development across multiple disease areas to estimate product value and optimize access for patients.

Gorana holds a PhD in Applied Statistics from Swiss Federal Institute of Technology in Lausanne, Switzerland and is Associate professor or research methodology at University of Split, Croatia.



Sreeram Ramagopalan
Global Head for Real World Evidence for Market Access
Roche (Basel, Switzerland)

Sreeram (Ram) Ramagopalan is the Global Head for Real World Evidence for Market Access at Roche. Dr Ramagopalan’s team strategically plans and executes real world research studies to obtain and maintain access for Roche medicines. Dr Ramagopalan holds a PhD in Epidemiology from the University of Oxford, as well as an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine. He is an international expert in real world evidence with over 270 peer reviewed publications. 



Allison Betof Warner
Assistant Attending Physician on the Melanoma Service
Memorial Sloan Kettering Cancer Center (NY, USA)

Allison Betof Warner, MD, PhD is an Assistant Attending Physician on the Melanoma Service at Memorial Sloan Kettering Cancer Center. Dr Betof graduated magna cum laude from Cornell University and went on to graduate with her MD/PhD from the Medical Scientist Training Program at Duke University. She completed her PhD under the supervision of Drs Mark Dewhirst and Lee Jones, studying tumor angiogenesis and effects of vascular normalization on chemotherapeutic efficacy. Dr Betof went on to Internal Medicine residency at Massachusetts General Hospital then Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Her research explores how modulations in tumor microenvironment affect tumor immunobiology and immunotherapy.

In association with: